Risk of tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax-containing regimens without dose ramp-up.
Rabia ShahswarGernot BeutelRazif GabdoullineChristian KoeneckeDominik MarkelMatthias EderMichael StadlerGudrun GohringBrigitte SchlegelbergerArne TrummerJuergen KrauterFelicitas TholMichael HeuserPublished in: Annals of hematology (2020)